The global non-PVC IV bags market size was valued at USD 1.51 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 9.8% from 2021 to 2028. Rising demand for preventive measures for errors, such as improper dose delivery, and augmented demand for advanced IV containers are among the major growth-driving factors of the market. Issues with traditional IV containers include drug-packaging material interactions and difficulties in transporting, handling, and disposing of containers. The majority of these issues can be prevented by using non-PVC IV bags. As a result, demand for the same is predicted to skyrocket during the forecast period.
Furthermore, there is a growing demand in the treatment of oncology processes, mainly for chemotherapy and for targeted drug delivery, as most of these therapeutic agents are prone to interaction with the plasticizers and have a tendency to convert into harmful agents. This discordancy can be minimalized by the use of containers without plasticizers. These bags are made of Polypropylene (PP) and Ethylene-Vinyl Acetate (EVA). Cancer treatment affects the human body by causing physical obstructions, GI dysfunction, and ulcers and deprives the human body of nutrition. Thus, they must be externally injected. The demand for IV bags has risen significantly owing to the increased cases of cancer.
For instance, according to the World Health Organization (WHO), cancer is the second leading cause of death across the world. It further stated that an estimated 9.6 million deaths, i.e., 1 in 6 deaths, were reported due to cancer in 2018. The American Cancer Society estimated that more than 1.7 million new cancer cases were diagnosed in America in 2019. From the data by Cancer Research U.K., every year 36,7000 new cases of cancer are reported in the U.K. Thus, the increasing prevalence of cancer is the most promising factor for the growth of the IV solutions market.
Several firms are turning to plasticizer-free, biologically inert materials to substitute the use of PVC (polyvinyl chloride). In the past 5 years, B. Braun has spent around USD 500.00 million in developing innovative ways to provide PVC and DEHP-free product lines. The development and availability of modern materials in different designs are expected to boost growth through the replacement of glass and PVC containers. In March 2021, Fagron Sterile Services U.S. (FSS), a 503B outsourcing leader, announced the addition of a new platform – intravenous (IV) bags – to its product portfolio.
The other factors supporting the market growth include the increasing reach of the local manufacturers in the global market, stringent regulations against the usage and disposal of PVC, and healthcare infrastructure development in emerging countries. Moreover, technological advances in service quality and an increased number of hospitals worldwide are few additional factors that drive the market. There have been growing concerns in the medical field of PVC IV bags posing a risk to human health and the environment due to phthalates leaching from equipment.
Furthermore, it results in the production of toxic HCL by disposal of PVC products using the incineration process. This further contributes to acid rainfall. Building IV bags, made of PVC-free material with thermal stability, moisture-barrier properties, and environmentally-friendly disposal are therefore made for companies like Baxter, Hospira, and B. Braun Melsungen AG. Hence, with the adoption of PVC-free IV bags, the healthcare industry can make a significant stride in protecting the health and safety of patients globally.
The single-chamber segment accounted for the largest revenue share of over 63% in 2020. The usage of single-chamber products is increasing constantly as IV bags replace other IV containers. The advent of non-PVC materials has accelerated the replacement of glass containers with plastic bags, owing to benefits, such as the ease of handling, transportation, and disposal. Irrigation fluids, drip bags, and sterile water are also commonly used intravenous solutions. As a result, single-chamber bags are widely used.
The multi-chambered segment is estimated to exhibit the fastest CAGR during the forecast period. Multi-chambered IV bags are preferred for intravenous therapy when a combination of medications must be administered to the patient. Multi-chamber products are manufactured from materials, such as non-PVC film with easy peel-off and fast-seal properties that are widely used in the healthcare industry for any emergency.
Moreover, these products are beneficial in the pharmaceutical industry as they lower the inefficiency of standard IV bags that are commonly used in the market. Furthermore, due to their excellent stability, high-pressure agility, outstanding transparency, toughness, and thermal sealing, as well as the fact that they are reusable, these bags are widely used in pharmaceuticals. Thus, growing product utility in several materials, such as parenteral nutrition and drug reconstitution, along with the availability of customized product offerings are expected to drive the multi-chambered segment growth.
The EVS segment held the largest revenue share of more than 33% in 2020 and is anticipated to witness considerable growth over the forecast period. It is the most widely used PVC alternative. The material is anticipated to be widely used in blood banks and the storage of frozen mixtures. Growing recognition and high demand for blood and blood component storage as a result of an increasing number of blood banks are projected to boost the segment growth over the forecast period.
Moreover, the demand for EVA infusion bags is expected to be driven by increased understanding of parenteral nutrition therapy and the high prevalence of Chronic Kidney Disease (CKD). For instance, according to the CDC, more than 1 in 7, that is 15% of the adult population in the U.S., or 37 million people, are likely to have CKD. Compounding fluids are delivered parenterally using EVA bags. Various medicines are sometimes combined using ingredients or drugs.
For instance, fluid from compounding parenteral nutrition and chemotherapy medications. The copolyester ether segment is projected to exhibit the fastest CAGR during the estimated period. Durability, transparency, chemical resistance, and the ability to withstand a variety of sterilization processes, such as autoclave, radiation, and electron beam, are some of the benefits associated with copolyester ether.
Copolyester ether’s strength is increased by the addition of other materials, such as PP and other polyolefin resins. The development of Ecdel elastomer has proven to be a watershed moment in the evolution of copolyester ether in pharmaceutical packaging. Abbott Laboratories, Sealed Air Corporation, B. Braun Melsungen AG, and Eastman Chemical Company are among the key companies engaged in developing these combinations.
The liquid mixture segment captured the largest revenue share of over 78% in 2020 and will retain the leading position throughout the forecast period. This growth can be credited to the implementation of novel designs and the high use of IV drips in hospitals. In the blood banks, there is an increasing demand for specialized IV containers, which resist low temperatures and offer greater security than PVC.
In addition, major players in the non-PVC IV bags market are concentrating on increasing their production to gain a higher market share. For instance, in November 2019, Grifols initiated the production at its novel blood-collection systems plant in Brazil with a capacity of more than 10 million blood collection bags yearly.
The market share obtained from non-PVC IV bags used for frozen mixes is very low. Bags of PVC tend to explode at low temperatures. However, EVA has been considered to be a successful alternative to the lower temperatures of PVC. Thus, the segment is estimated to register the fastest CAGR from 2021 to 2028. Some examples of frozen mixture include methylprednisolone, cefazolin, ceftriaxone, nafcillin, and nicardipine hydrochloride.
North America captured the largest revenue share of more than 46% in 2020. In the U.S., strict regulations aimed at improving patient safety have increased the demand for non-PVC IV containers, which provide treatments without any harm. Moreover, the demand for IV bags has risen significantly due to the increased prevalence of stomach cancer. For instance, the American Cancer Society estimated that in 2020 there were about 27,600 cases of stomach cancer in the U.S. The patients suffering from stomach cancer are unable to ingest food through the mouth and thus have to entirely rely on total parenteral solutions for dietary needs and survival. This might surge the demand for EVA infusion bags, which, in turn, is expected to boost the regional market. In addition, the rising adoption of novel drug delivery systems and technological innovations are anticipated to push the market growth in this region.
Asia Pacific is expected to be the fastest-growing regional market during the forecast period. The advent of local manufacturers that encourage international demand by selling goods at affordable rates, increased foreign direct investment, and rapid improvement in healthcare infrastructure, including a rise in the number of hospitals, clinics, and blood banks, are all factors that are having a significant effect on the industry’s growth.
Key players are involved in adopting strategies, such as mergers & acquisitions, partnerships, and new product launches to strengthen their foothold in the global market. For instance, in July 2019, Baxter received the U.S. FDA approval for Myxredlin, the 1st and only ready-to-use insulin for IV infusion.
Key players are investing heavily in R&D to manufacture technologically advanced products. For instance, in May 2019, Sihuan Pharmaceutical Holdings Group Ltd. launched the “non-PVC solid-liquid double chamber bag for ceftazidime/sodium chloride injection” cooperatively developed by the Group and its associated company Beijing Ruiye Drugs Manufacture Co. Ltd. The National Medical Products Administration (NMPA) of the People’s Republic of China has approved it for drug registration. In China, the Group is the first to obtain certification for a “non-PVC solid-liquid double chamber bag for ceftazidime/sodium chloride injection. Some prominent players in the global non-PVC IV bags market include:
- Angiplast Pvt. Ltd.
- Shanghai Xin Gen Eco-Technologies Co., Ltd.
- Jiangxi Sanxin Medtec Co., Ltd.
- PolyCine GmbH
- Kraton Corp.
- B. Braun Melsungen AG
- Pfizer, Inc.
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global non-PVC IV bags market report on the basis of product, material, content, and region:
- Product Outlook (Revenue, USD Million, 2016 – 2028)
- Single Chamber
- Multi Chamber
- Material Outlook (Revenue, USD Million, 2016 – 2028)
- Ethylene Vinyl Acetate (EVA)
- Copolyester Ether
- Content Outlook (Revenue, USD Million, 2016 – 2028)
- Frozen Mixture
- Liquid Mixture
- Regional Outlook (Revenue, USD Million, 2016 – 2028)
- North America
- Asia Pacific
- Latin America
- South Africa
- Saudi Arabia
- North America